Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case Series

We repurposed the antifibrotic drug pirfenidone—which is approved for treatment of idiopathic lung fibrosis—in a series of patients with nonalcoholic steatohepatitis-related cirrhosis. Our report demonstrates the observed improvements in necroinflammation and regression of cirrhosis with pirfenidone...

Descripción completa

Detalles Bibliográficos
Autores principales: Philips, Cyriac Abby, Padsalgi, Guruprasad, Ahamed, Rizwan, Paramaguru, Rajaguru, Rajesh, Sasidharan, George, Tom, Mahadevan, Pushpa, Augustine, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132022/
https://www.ncbi.nlm.nih.gov/pubmed/32274350
http://dx.doi.org/10.14218/JCTH.2019.00056
Descripción
Sumario:We repurposed the antifibrotic drug pirfenidone—which is approved for treatment of idiopathic lung fibrosis—in a series of patients with nonalcoholic steatohepatitis-related cirrhosis. Our report demonstrates the observed improvements in necroinflammation and regression of cirrhosis with pirfenidone use for 12-weeks, associated with classical hepatic repair complex features on follow-up liver biopsies. This novel work could help stimulate further randomized trials of pirfenidone in patients with nonalcoholic steatohepatitis-related liver fibrosis or cirrhosis, for whom no recommended drug treatments exists currently.

Ejemplares similares